Marc Castelltort

Marc Castelltort

Company: Senolytic Therapeutics Inc

Job title: Co-founder and CEO


Marc is a co-founder and CEO at Senolytic Therapeutics Inc., a pharmaceutical company that develops a novel class of medicines by targeting senescence cells. He also holds a position as senior advisor for new investments in Europe at Life Biosciences Inc., an aging-focused investment firm. Currently, Marc is also a board advisor at Cebiotex, Retinset Therapeutics and Origen Ventures. He is a co-founder and Partner at Chasing Science, an incubator for early-stage biomedicine ventures between Boston and Barcelona. He is a founder and advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. Marc is a strategic advisor and board member for multiple organizations and a co-founder of several companies in the past. Marc has also implemented Entrepreneurs-in-Residence programs at the UPV and IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets). Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.


Panel Discussion: Tackling Preclinical & Translational Challenges in Aging-Related Therapeutics 11:15 am

How applicable to human aging is any given result in a model organism? How to promote advances in biomarker discovery and validation in aging Defining routes for translational success from discovery to clinic – what will be the key factors for generating successful results? Standardizing different classes of therapeutic approaches to achieve effective anti-aging outcomesRead more

day: Day Two

The Challenge of Developing Novel Senolytic Medicines 11:30 am

Exploring cellular senescence: fibrosis and cancer Describing our approach to design senolytic medicines STX077 targeted therapy: a versatile drug delivery system STX255 immuno-senescence approachRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.